Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HUMA
Strong SellSinkerHumacyte, Inc. · Healthcare · United States · $181M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Humacyte, Inc. is a clinical-stage biotechnology company developing bioengineered human acellular vessels (HAVs) for vascular repair, reconstruction, and replacement. Its proprietary technology aims to create off-the-shelf, universally implantable vessels that avoid rejection, addressing significant unmet needs in vascular surgery. The company holds a unique position in regenerative medicine with the potential to offer a superior alternative to synthetic grafts and autologous vessels.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.0M | — | 2.1M | 3.5M | 22.4M | 231.3% |
| EPS | -0.05 | -0.41 | -0.61 | -0.26 | — | -0.52 | -0.40 | -0.25 | — |
| Shares | 269.6M | 269.6M | 269.6M | 193.0M | -28.4% | — | — | — | — |
| Debt | 50.1M | 18.9M | 16.5M | 64.8M | 9.0% | 66.9M | — | — | — |
| Equity | 116.9M | 13.5M | -52.7M | 3.1M | -70.2% | — | — | — | — |
| Op CF | -71.1M | -73.3M | -98.1M | -105.0M | — | -97.2M | — | — | — |
| Inv CF | 4.8M | -0.2M | -1.6M | -0.9M | — | — | — | — | — |
| Fin CF | -1.4M | 4.5M | 114.2M | 61.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HUMA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HUMA | Humacyte, Inc.(you) | $181M | 2 | Strong Sell |
| ARMP | Armata Pharmaceuticals, Inc. | $200M | 1 | Strong Sell |
| 2592.HK | Cloudbreak Pharma Inc. | $136M | 1 | Strong Sell |
| GLSI | Greenwich LifeSciences, Inc. | $230M | 4 | Strong Sell |
| INO | Inovio Pharmaceuticals, Inc. | $133M | 3 | Strong Sell |
| CNTN | Canton Strategic Holdings, Inc. | $177M | 8 | Strong Sell |
| CBUS | Cibus, Inc. | $126M | 2 | Strong Sell |
| NTHI | NeOnc Technologies Holdings, Inc. | $122M | 0 | Strong Sell |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $211M | 7 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 6 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%